Login
- Titel:
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression.
- Dokumenttyp:
- Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Article
- Autor(en):
- Perner, S; Hofer, MD; Kim, R; Shah, RB; Li, H; Möller, P; Hautmann, RE; Gschwend, JE; Kuefer, R; Rubin, MA
- Abstract:
- Distinguishing aggressive prostate cancer from indolent disease represents an important clinical challenge, because current therapy may lead to overtreatment of men with limited disease. The prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein that is highly restricted to the prostate. Previously, studies analyzing the expression of PSMA have found an up-regulation in correlation with prostate cancer, particularly in advanced cancer. This association is ideal for an application as a prognostic marker. In the current study, we characterized PSMA expression in a high-risk cohort and evaluated its potential use as predictive marker of prostate-specific antigen (PSA) recurrence. PSMA expression was analyzed by immunohistochemistry using tissue microarrays composed of tumor samples from 450 patients. Protein intensity was recorded using a semiautomated quantitative microscope system (ACIS II; Clarient Chromavision Medical Systems, San Juan Capistrano, CA). PSMA expression levels differed significantly (P < .001) between benign prostatic tissue, localized prostate cancer, and lymph node metastases. Dividing the cohort into high- and low-PSMA expressing cancers based on the median area of positive staining, we found that high PSMA levels were associated with significant increase of PSA recurrence (P = .004). This was independent of clinical parameters such as lymph node tumor burden (lymph node density, >20%; P < .001), extraprostatic extension (P = .017), seminal vesicle invasion (P < .001), and high Gleason score (8-10, P = .006). In a multivariate model, PSMA expression and metastases to pelvic lymph nodes were significantly associated with time to PSA recurrence (HR, 1.4; 95% confidence interval, 1.1-2.8, P = .017; and hazard ratio, 5; 95% confidence interval, 2.6-9.7, P < .001, respectively). In summary, PSMA is independently associated with PSA recurrence in a high-risk cohort and thus might provide insight into the additional use of adjuvant therapy. Validation on other cohorts is required.
- Zeitschriftentitel:
- Hum Pathol
- Jahr:
- 2007
- Band / Volume:
- 38
- Heft / Issue:
- 5
- Seitenangaben Beitrag:
- 696-701
- Sprache:
- eng
- Volltext / DOI:
- doi:10.1016/j.humpath.2006.11.012
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/17320151
- Print-ISSN:
- 0046-8177
- TUM Einrichtung:
- Urologische Klinik und Poliklinik
BibTeX